

Zuzana Walker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1123383/publications.pdf>

Version: 2024-02-01

138
papers

11,618
citations

36203

51
h-index

30010

103
g-index

144
all docs

144
docs citations

144
times ranked

10417
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.5	2,805
2	Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. <i>Lancet Neurology</i> , The, 2007, 6, 305-313.	4.9	598
3	Lewy body dementias. <i>Lancet</i> , The, 2015, 386, 1683-1697.	6.3	422
4	Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. <i>Lancet Neurology</i> , The, 2009, 8, 613-618.	4.9	420
5	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, 743-755.	1.5	365
6	Depression in older adults. <i>BMJ: British Medical Journal</i> , 2011, 343, d5219-d5219.	2.4	299
7	EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 443-450.	3.3	263
8	Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1176-1181.	0.9	250
9	Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 73, 134-140.	0.9	239
10	Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density. <i>JAMA Neurology</i> , 2015, 72, 287.	4.5	238
11	Microglia, Amyloid, and Glucose Metabolism in Parkinson's Disease with and without Dementia. <i>Neuropsychopharmacology</i> , 2013, 38, 938-949.	2.8	202
12	Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. <i>International Psychogeriatrics</i> , 2009, 21, 813.	0.6	188
13	Islington study of dementia subtypes in the community. <i>British Journal of Psychiatry</i> , 2002, 180, 270-276.	1.7	185
14	START (STrAtegies for RelaTives) study: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manual-based coping strategy programme in promoting the mental health of carers of people with dementia. <i>Health Technology Assessment</i> , 2014, 18, 1-242.	1.3	156
15	Long-Term Use of Rivastigmine in Patients With Dementia With Lewy Bodies: An Open-Label Trial. <i>International Psychogeriatrics</i> , 2001, 13, 199-205.	0.6	155
16	Clinical effectiveness of a manual based coping strategy programme (START, STrAtegies for RelaTives) in promoting the mental health of carers of family members with dementia: pragmatic randomised controlled trial. <i>BMJ</i> , The, 2013, 347, f6276-f6276.	3.0	154
17	European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain ¹⁸ F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. <i>European Journal of Neurology</i> , 2018, 25, 1201-1217.	1.7	153
18	Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease. <i>Neurology</i> , 2004, 62, 1568-1572.	1.5	143

#	ARTICLE	IF	CITATIONS
19	Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease. <i>Brain</i> , 2018, 141, 2740-2754.	3.7	143
20	Diagnostic accuracy of ¹²³ I-FP-CIT SPECT in possible dementia with Lewy bodies. <i>British Journal of Psychiatry</i> , 2009, 194, 34-39.	1.7	135
21	Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2000, 15, 387-392.		129
22	Olanzapine in dementia with Lewy bodies: a clinical study. <i>International Journal of Geriatric Psychiatry</i> , 1999, 14, 459-466.	1.3	121
23	Abuse of people with dementia by family carers: representative cross sectional survey. <i>BMJ: British Medical Journal</i> , 2009, 338, b155-b155.	2.4	119
24	Autopsy validation of ¹²³ I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. <i>Neurology</i> , 2017, 88, 276-283.	1.5	118
25	The determinants of family carers' abusive behaviour to people with dementia: Results of the CARD study. <i>Journal of Affective Disorders</i> , 2010, 121, 136-142.	2.0	107
26	Neuropsychological performance in Lewy body dementia and Alzheimer's disease. <i>British Journal of Psychiatry</i> , 1997, 170, 156-158.	1.7	98
27	Predictors of Age of Diagnosis and Survival of Alzheimer's Disease in Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 717-728.	1.2	94
28	Long-term outcome of depressive pseudodementia in the elderly. <i>Journal of Affective Disorders</i> , 2007, 101, 123-129.	2.0	88
29	Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 1063-1070.	0.9	88
30	Violent Incidents in a Psychiatric Intensive Care Unit. <i>British Journal of Psychiatry</i> , 1994, 164, 826-828.	1.7	87
31	Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1534-1545.	3.3	86
32	The functional anatomy of divided attention in amnesic mild cognitive impairment. <i>Brain</i> , 2005, 128, 1418-1427.	3.7	83
33	Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1509-1525.	3.3	81
34	What to tell dementia caregivers – the rule of threes. <i>International Journal of Geriatric Psychiatry</i> , 2003, 18, 313-317.	1.3	77
35	Dementia diagnostic criteria in Down syndrome. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 857-863.	1.3	77
36	Dopamine transporter single photon emission computerized tomography in the diagnosis of dementia with Lewy bodies. <i>Movement Disorders</i> , 2009, 24, S754-9.	2.2	75

#	ARTICLE	IF	CITATIONS
37	Use of Flutemetamol F 18 ⁺ -Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnesic Mild Cognitive Impairment. <i>JAMA Neurology</i> , 2018, 75, 1114.	4.5	75
38	Subjective cognitive impairment: Functional MRI during a divided attention task. <i>European Psychiatry</i> , 2011, 26, 457-462.	0.1	74
39	In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies. <i>Lancet, The</i> , 1999, 354, 646-647.	6.3	73
40	Subjective cognitive impairment: increased prefrontal cortex activation compared to controls during an encoding task. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 865-874.	1.3	73
41	Risperidone for psychotic and behavioural symptoms in Lewy body dementia. <i>Lancet, The</i> , 1995, 346, 185.	6.3	69
42	Dopamine transporter binding in Gilles de la Tourette syndrome: a [123I]FP-CIT/SPECT study. <i>Acta Psychiatrica Scandinavica</i> , 2004, 109, 140-146.	2.2	69
43	Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 787-795.	1.2	69
44	Long-term clinical and cost-effectiveness of psychological intervention for family carers of people with dementia: a single-blind, randomised, controlled trial. <i>Lancet Psychiatry</i> , the, 2014, 1, 539-548.	3.7	68
45	Cost effectiveness of a manual based coping strategy programme in promoting the mental health of family carers of people with dementia (the START (STrategies for RelaTives) study): a pragmatic randomised controlled trial. <i>BMJ, The</i> , 2013, 347, f6342-f6342.	3.0	67
46	Family carers' distress and abusive behaviour: longitudinal study. <i>British Journal of Psychiatry</i> , 2010, 196, 480-485.	1.7	65
47	Clinical utility of FDG-PET for the clinical diagnosis in MCI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1497-1508.	3.3	61
48	A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium. <i>Alzheimer's and Dementia</i> , 2019, 15, 400-409.	0.4	60
49	Three years survival in patients with a clinical diagnosis of dementia with Lewy bodies. , 2000, 15, 267-273.		59
50	Performance of [¹⁸ F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA ⁺ AA recommendations for the neuropathologic diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 25-34.	1.2	57
51	EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 434-442.	3.3	56
52	Dementia with Lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon mission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 609-614.	2.2	55
53	Relationship of exercise and other risk factors to depression of Alzheimer's disease: the LASER-AD study. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 261-268.	1.3	53
54	Oxidative stress and cognitive ability in adults with Down syndrome. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 76-80.	2.5	52

#	ARTICLE	IF	CITATIONS
55	A complex multimodal activity intervention to reduce the risk of dementia in mild cognitive impairmentâ€”ThinkingFit: pilot and feasibility study for a randomized controlled trial. <i>BMC Psychiatry</i> , 2014, 14, 129.	1.1	52
56	Clinical usefulness of dopamine transporter SPECT imaging with ¹²³ I-FP-CIT in patients with possible dementia with Lewy bodies: Randomised study. <i>British Journal of Psychiatry</i> , 2015, 206, 145-152.	1.7	52
57	Prodromal Dementia with Lewy Bodies and Prodromal Alzheimerâ€™s Disease: A Comparison of the Cognitive and Clinical Profiles. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 463-470.	1.2	48
58	The Effect of Mindfulness-based Programs on Cognitive Function in Adults: A Systematic Review and Meta-analysis. <i>Neuropsychology Review</i> , 2022, 32, 677-702.	2.5	48
59	An fMRI study of verbal episodic memory encoding in amnesic mild cognitive impairment. <i>Cortex</i> , 2008, 44, 869-880.	1.1	47
60	Oxidative Stress and Memory Decline in Adults with Down Syndrome: Longitudinal Study. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 277-283.	1.2	42
61	Efficacy of lifestyle and psychosocial interventions in reducing cognitive decline in older people: Systematic review. <i>Ageing Research Reviews</i> , 2020, 62, 101113.	5.0	42
62	Antidepressant Treatment of Chronic Tension-Type Headache: A Comparison Between Fluoxetine and Desipramine. <i>Headache</i> , 1998, 38, 523-528.	1.8	41
63	Clinical use of structural magnetic resonance imaging in the diagnosis of dementia in adults with Down's syndrome. <i>Irish Journal of Psychological Medicine</i> , 2002, 19, 60-63.	0.7	41
64	Dementia with Lewy bodies versus Alzheimer's disease: Role of dopamine transporter imaging. <i>Movement Disorders</i> , 2003, 18, S34-S38.	2.2	41
65	Do patients with young onset Alzheimer's disease deteriorate faster than those with late onset Alzheimer's disease? A review of the literature. <i>International Psychogeriatrics</i> , 2014, 26, 1945-1953.	0.6	40
66	AMYPAD Diagnostic and Patient Management Study: Rationale and design. <i>Alzheimer's and Dementia</i> , 2019, 15, 388-399.	0.4	37
67	Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials. <i>BMJ Open</i> , 2014, 4, e005122-e005122.	0.8	35
68	Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1557-1566.	3.3	35
69	Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimerâ€™s disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1487-1496.	3.3	35
70	¹¹ C-PIB PET in subjective cognitive impairment. <i>European Psychiatry</i> , 2010, 25, 123-125.	0.1	34
71	Factors that predict cognitive decline in patients with subjective cognitive impairment. <i>International Psychogeriatrics</i> , 2015, 27, 1671-1677.	0.6	33
72	Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer's disease: a cohort study. <i>BMJ Open</i> , 2012, 2, e000380.	0.8	31

#	ARTICLE	IF	CITATIONS
73	Vitamins, Trace Elements, and Antioxidant Status in Dementia Disorders. <i>International Psychogeriatrics</i> , 2001, 13, 265-275.	0.6	29
74	Late onset depression: dopaminergic deficit and clinical features of prodromal Parkinson's disease: a cross-sectional study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 158-164.	0.9	29
75	Impact of cholinesterase inhibitors or memantine on survival in adults with Down syndrome and dementia: clinical cohort study. <i>British Journal of Psychiatry</i> , 2018, 212, 155-160.	1.7	28
76	Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1526-1533.	3.3	28
77	Clinical effectiveness of the START (STrategies for RelaTives) psychological intervention for family carers and the effects on the cost of care for people with dementia: 6-year follow-up of a randomised controlled trial. <i>British Journal of Psychiatry</i> , 2020, 216, 35-42.	1.7	27
78	The SCD-Well randomized controlled trial: Effects of a mindfulness-based intervention versus health education on mental health in patients with subjective cognitive decline (SCD). <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 737-745.	1.8	26
79	A memory clinic for older people with intellectual disabilities. <i>Aging and Mental Health</i> , 2003, 7, 418-423.	1.5	24
80	Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1546-1556.	3.3	24
81	Secrets and lies: the dilemma of disclosing the diagnosis to an adult with dementia. <i>Age and Ageing</i> , 2003, 32, 439-441.	0.7	23
82	Exploring the experiences of people with mild cognitive impairment and their caregivers with particular reference to healthcare – a qualitative study. <i>International Psychogeriatrics</i> , 2014, 26, 475-485.	0.6	23
83	Endogenous Antioxidant Activities in Relation to Concurrent Vitamins A, C, and E Intake in Dementia. <i>International Psychogeriatrics</i> , 2002, 14, 7-15.	0.6	20
84	Safety Analysis of 10 Clinical Trials and for 13 Years After First Approval of Ioflupane 123I Injection (DaTscan). <i>Journal of Nuclear Medicine</i> , 2014, 55, 1281-1287.	2.8	19
85	A Double-Blind Randomized Placebo-Controlled Withdrawal Trial Comparing Memantine and Antipsychotics for the Long-Term Treatment of Function and Neuropsychiatric Symptoms in People With Alzheimer's Disease (MAIN-AD). <i>Journal of the American Medical Directors Association</i> , 2015, 16, 316-322.	1.2	19
86	Data quality, floor and ceiling effects, and test-retest reliability of the Mild Cognitive Impairment Questionnaire. <i>Patient Related Outcome Measures</i> , 2018, Volume 9, 43-47.	0.7	19
87	Prediction of survival in Alzheimer's disease – The LASER-AD longitudinal study. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 739-747.	1.3	18
88	Effects of a Mindfulness-Based Intervention versus Health Self-Management on Subclinical Anxiety in Older Adults with Subjective Cognitive Decline: The SCD-Well Randomized Superiority Trial. <i>Psychotherapy and Psychosomatics</i> , 2021, 90, 341-350.	4.0	18
89	Memory Decline in Down Syndrome and Its Relationship to iPF2alpha, a Urinary Marker of Oxidative Stress. <i>PLoS ONE</i> , 2014, 9, e97709.	1.1	17
90	Individual-Reader Diagnostic Performance and Between-Reader Agreement in Assessment of Subjects with Parkinsonian Syndrome or Dementia Using ¹²³ I-Ioflupane Injection (DaTscan) Imaging. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1288-1296.	2.8	17

#	ARTICLE	IF	CITATIONS
91	Attitudes to depression in hospital inpatients: A comparison between older and younger subjects. <i>Aging and Mental Health</i> , 1998, 2, 36-39.	1.5	16
92	Ten years of cholinesterase inhibitors. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 437-442.	1.3	16
93	Memory Complaints with and without Memory Impairment: The Impact of Leukoaraiosis on Cognition. <i>Journal of the International Neuropsychological Society</i> , 2011, 17, 1104-1112.	1.2	16
94	Evolution of clinical features in possible DLB depending on FP-CIT SPECT result. <i>Neurology</i> , 2016, 87, 1045-1051.	1.5	14
95	Psychiatric morbidity in elderly attenders at an accident and emergency department. <i>International Journal of Geriatric Psychiatry</i> , 1995, 10, 951-957.	1.3	13
96	Appropriate use criteria for amyloid PET imaging cannot replace guidelines: On behalf of the European Association of Nuclear Medicine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1122-1125.	3.3	13
97	Do cerebral white matter lesions influence the rate of progression from mild cognitive impairment to dementia?. <i>International Psychogeriatrics</i> , 2013, 25, 120-127.	0.6	13
98	The development and validation of a patient-reported quality of life measure for people with mild cognitive impairment. <i>International Psychogeriatrics</i> , 2014, 26, 487-497.	0.6	13
99	APPLEtree (Active Prevention in People at risk of dementia: Lifestyle, bEhaviour change and Technology) Tj ETQq1 1 0.784314 rgBT <i>Psychiatry</i> , 2020, 35, 811-819.	1.3	13
100	¹²³ I-FP-CIT SPECT in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease: a new quantitative analysis of autopsy confirmed cases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 662-667.	0.9	13
101	Imaging in neurodegenerative disorders: recent studies. <i>Current Opinion in Psychiatry</i> , 2005, 18, 640-646.	3.1	12
102	Falling through the cracks: Stakeholders' views around the concept and diagnosis of mild cognitive impairment and their understanding of dementia prevention. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 1349-1357.	1.3	12
103	The Mini-SIB: a short scale for measuring cognitive function in severe dementia. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 1001-1002.	1.3	10
104	Attitudes of UK psychiatrists to the diagnosis of MCI in clinical practice. <i>International Psychogeriatrics</i> , 2013, 25, 286-291.	0.6	10
105	Dementia with Lewy Bodies: Clinical Characteristics and Diagnostic Criteria. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2002, 15, 188-194.	1.2	9
106	Higher fat and carbohydrate intake in dementia patients is associated with increased blood glutathione peroxidase activity. <i>International Psychogeriatrics</i> , 2005, 17, 91-98.	0.6	9
107	Dopaminergic imaging: clinical utility now and in the future. <i>International Psychogeriatrics</i> , 2011, 23, S32-S40.	0.6	9
108	In vivo Dopamine Pre-Synaptic Receptors and Antioxidant Activities in Patients with Alzheimer's Disease, Dementia with Lewy Bodies and in Controls. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 16, 46-51.	0.7	8

#	ARTICLE	IF	CITATIONS
109	Magnetic Resonance Imaging in Stable Mild Cognitive Impairment, Prodromal Alzheimer's Disease, and Prodromal Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 583-588.	0.7	8
110	Trends in referred patient profiles in a memory clinic over 20 years. <i>Dementia</i> , 2016, 15, 789-797.	1.0	7
111	Author response: Autopsy validation of [¹²³ I]-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. <i>Neurology</i> , 2017, 89, 751-751.	1.5	6
112	[¹²³ I]-FP-CIT dopaminergic neuroimaging for the diagnosis of dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2012, 8, 74-83.	0.4	5
113	Analyzing large Alzheimer's disease cognitive datasets: Considerations and challenges. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12135.	1.2	5
114	The effect of remotely delivered lifestyle interventions on cognition in older adults without dementia: A systematic review and meta-analysis. <i>Ageing Research Reviews</i> , 2021, 72, 101505.	5.0	5
115	Dietary and endogenous antioxidants in dementia. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 639-641.	1.3	3
116	Dementia with Lewy bodies. <i>British Journal of Neuroscience Nursing</i> , 2015, 11, 146-149.	0.1	3
117	Dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 310-311.	1.5	3
118	Letter to the editor. <i>Journal of Intellectual Disability Research</i> , 2004, 48, 769-770.	1.2	2
119	The Development and Validation of a Quality of Life Measure for People with Mild Cognitive Impairment (The MCQ). <i>Value in Health</i> , 2013, 16, A550.	0.1	2
120	Lewy Body Dementias. <i>Focus (American Psychiatric Publishing)</i> , 2017, 15, 85-100.	0.4	2
121	Dementia with Lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 609-614.	3.3	2
122	SPECT/PET Findings in Lewy Body Dementia. , 2014, , 373-415.		2
123	Quantitative amyloid PET in the AMYPAD diagnostic and patient management study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
124	Cardiopulmonary resuscitation and other life supporting measures in elderly patients: Attitudes of psychiatrists and geriatricians. <i>Ageing and Mental Health</i> , 1999, 3, 336-339.	1.5	1
125	Long-term outcome of depressive pseudodementia in the elderly. <i>European Psychiatry</i> , 2007, 22, S25.	0.1	1
126	The effect of a mindfulness-based versus health self-management intervention on cognitive performance in older adults with subjective cognitive decline (SCD): The SCD-Well randomized controlled trial. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1

#	ARTICLE	IF	CITATIONS
127	Self-reflection is associated with markers of Alzheimer's disease in cognitively unimpaired older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
128	Laterality in Parkinson's disease and susceptibility to psychosis. <i>Schizophrenia Research</i> , 1997, 24, 22.	1.1	0
129	Neuroimaging and the Psychiatry of Late Life Edited by David Ames & Edmond Chiu. Cambridge: Cambridge University Press. 1997. 226 pp. £60.00 (US\$95.00) (hb). ISBN 0-521-49505-9. <i>British Journal of Psychiatry</i> , 1999, 175, 296-296.	1.7	0
130	Six years experience with acetylcholinesterase inhibitors in a clinical setting. <i>European Psychiatry</i> , 2007, 22, S305.	0.1	0
131	624 " Association of apathy with caregiver burden in amnesic mild cognitive impairment. <i>European Psychiatry</i> , 2013, 28, 1.	0.1	0
132	O4-06-03: PREVALENCE OF DLB FEATURES IN POSSIBLE DEMENTIA WITH LEWY BODIES AND ITS RELATIONSHIP TO CHANGES IN DEMENTIA DIAGNOSTIC CATEGORY AFTER DOPAMINE TRANSPORTER IMAGING USING DATSCAN, ., 2014, 10, P262-P262.		0
133	Authors' reply. <i>British Journal of Psychiatry</i> , 2015, 207, 364-365.	1.7	0
134	Dopamine Transporter Imaging. , 2017, , 141-155.		0
135	Author's reply to: Difficulties of diagnosing and managing dementia in people with Down syndrome. <i>British Journal of Psychiatry</i> , 2018, 213, 669-669.	1.7	0
136	Author's reply. <i>British Journal of Psychiatry</i> , 2018, 213, 667-668.	1.7	0
137	Dementia with Lewy Bodies. , 2019, , 88-100.		0
138	SPECT/PET Findings in Dementia with Lewy Bodies. , 2021, , 515-561.		0